Millennium Management
CSTL icon

Millennium Management’s Castle Biosciences CSTL Stock Holding History

Millennium Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-460,000
Closed -$10M – 6153
2024
Q2 		$10M Buy
+460,000
New +$10.3M ﹤0.01% 2076
2022
Q4 		– Sell
-50,000
Closed -$1.3M – 6635
2022
Q3 		$1.3M Buy
+50,000
New +$1.4M ﹤0.01% 4115

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management's CSTL Position: Q1 2026 in Review

Millennium Management increased its Castle Biosciences (CSTL) stake by 14% in Q1 2026, buying an estimated $1.45M and bringing the position to 353,319 shares worth $8.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2311.

Millennium Management first reported a position in CSTL in Q3 2019 and has held it in 25 quarters since. The position peaked at $32.5M in Q4 2020. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Millennium Management held 353,319 shares of Castle Biosciences worth $8.67M as of Q1 2026.
  • Millennium Management bought 44,405 Castle Biosciences shares in Q1 2026, an estimated $1.45M.
  • Castle Biosciences made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2311 holding.
  • Millennium Management first reported a position in Castle Biosciences in Q3 2019 and has held it in 25 quarters since.
  • Millennium Management's Castle Biosciences position peaked at $32.5M in Q4 2020.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.